Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib

Leuk Lymphoma. 2021 Feb;62(2):495-497. doi: 10.1080/10428194.2020.1832671. Epub 2020 Oct 14.

Authors

Alejandro Garcia-Horton¹, Elliot Smith¹, Dawn Maze¹, Caroline McNamara¹, Hassan Sibai¹, Vikas Gupta¹

Affiliation

¹ Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

PMID: 33459565
DOI: 10.1080/10428194.2020.1832671

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

DNA, Viral
Hepatitis B Antibodies
Hepatitis B Surface Antigens
Hepatitis B virus
Hepatitis B* / complications
Humans
Neoplasms*
Nitriles
Pyrazoles / adverse effects
Pyrimidines
Virus Activation

Substances

DNA, Viral
Hepatitis B Antibodies
Hepatitis B Surface Antigens
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib